Here’s Why Artisan Partners Reduced its Genmab A/S (GMAB) Position

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded here. A return of -2.36% was recorded by its Investor Class: ARTMX, -2.32% by its Advisor Class: APDMX, and -2.30% by its Institutional Class: APHMX, in the fourth quarter of 2020, all below the Russell Midcap® Growth Index that delivered a -0.57% return and the Russell Midcap® Index that was up by 8.14% for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

Artisan Mid Cap Fund, in its Q1 2021 investor letter, mentioned Genmab A/S (NASDAQ: GMAB), and shared their insights on the company. Genmab A/S is a Copenhagen, Denmark-based biotechnology company that currently has a $23.8 billion market capitalization. Since the beginning of the year, GMAB delivered a -8.46% return, while its 12-month gains are up by 35.25%. As of May 06, 2021, the stock closed at $37.22 per share.

Here is what Artisan Mid Cap Fund has to say about Genmab A/S in its Q1 2021 investor letter:

“We also reduced our position in Genmab. Genmab is a creator and developer of human antibody products for the treatment of life-threatening and debilitating diseases. The company is seeing solid adoption for its multiple myeloma drug, Darzalex FASPROTM, and its earlier stage pipeline contains multiple promising new cancer medicines. However, we trimmed our position based on our concern the stock price was not reflecting the risk of a negative outcome in the ongoing dispute with partner J&J (currently in arbitration) over Darzalex royalty terms. Following the stock’s subsequent selloff, we believe this risk is adequately discounted and are maintaining our current position.”


Our calculations show that Nasdaq, Inc. (NASDAQ: NDAQ) does not belong in our list of the 30 Most Popular Stocks Among Hedge Funds. As of the end of the fourth quarter of 2020, Nasdaq, Inc. was in 16 hedge fund portfolios, compared to 18 funds in the third quarter. NDAQ delivered a -8.26% return in the past 3 months.

The top 10 stocks among hedge funds returned 231.2% between 2015 and 2020, and outperformed the S&P 500 Index ETFs by more than 126 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Here you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 15 best innovative stocks to buy to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:

Disclosure: None. This article is originally published at Insider Monkey.